Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 602 participants.
Also called NCT04981041
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 602 participants
- Registry
-
NCT04981041
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Germany
- Registry status
- Completed
Technical summary
Registry record NCT04981041. Randomized; single masking; primary purpose treatment. Start 2021-12-16 (actual); primary completion 2026-05-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
- Acronym
- EPIDAURUS
- Condition
- Acute Coronary Syndrome
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Prasugrel or Ticagrelor
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Ludwig-Maximilians - University of Munich
Record details
- Record id
cardio:ct-nct04981041- Content hash
9285000bf7dffabc0172edbc07259656f3fcbf5d41baa2a5f86d01835f31e69c